慢性肾病患者多支冠脉血运重建:外科与经皮冠状动脉介入比较
本研究比较了慢性肾病合并多支冠状动脉病变患者接受冠状动脉旁路移植术(CABG)或经皮冠状动脉介入(PCI)的结局。纳入2010至2017年单中心1853例患者(CABG 1269例,PCI 584例),CABG与更高的5年无主要不良心脑血管事件(MACCE)生存率相关,倾向性匹配后结果一致。
要点
- CABG与更高的5年无MACCE生存率相关(70.1% vs 47.3%)。
- 倾向性匹配后CABG组5年生存率更高(73.9% vs 52.3%)。
- CABG组再入院、心肌梗死和再次血运重建率更低。
核心结论
- 在慢性肾病合并多支冠状动脉病变患者中,CABG与比PCI更低的MACCE率相关。
研究设计与样本
- 单中心回顾性研究,纳入2010至2017年接受CABG或PCI的慢性肾病合并多支冠状动脉病变患者1853例(CABG 1269例,PCI 584例)。
- 采用多变量Cox回归模型进行风险调整,并进行倾向性匹配分析。
主要发现
- CABG组5年无MACCE率为70.1%,PCI组为47.3%(P < 0.0001),风险调整后结果持续。
- CABG组早期和晚期死亡率及再入院率均低于PCI组,心肌梗死和再次血运重建的单独发生率也较低。
- 倾向性匹配后生成704例匹配患者(每组352例),CABG组5年无MACCE率为72.8%,PCI组为45.8%(P < 0.0001)。
- 匹配后CABG组5年生存率为73.9%,PCI组为52.3%(P < 0.0001);再入院原因特异性风险比为0.68(95%CI 0.58-0.80;P < 0.0001)。
- 匹配后CABG组心肌梗死发生率为2.6%,PCI组为9.7%(P < 0.0001);再次血运重建率为1.1% vs 7.4%(P < 0.0001)。
临床怎么用
- 对于慢性肾病合并多支冠状动脉病变患者,CABG可能优于PCI,应纳入多学科讨论以制定最佳血运重建策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study compared contemporary outcomes following surgical versus percutaneous coronary revascularization for multivessel coronary artery disease (MVCAD) in patients with chronic kidney disease. METHODS: Patients with MVCAD and a reduced glomerular filtration rate (<60 ml/min) undergoing coronary bypass surgery (CABG) or percutaneous coronary intervention (PCI) at a single institution between 2010 and 2017 were included. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE) defined as a composite outcome of death, stroke, myocardial infarction or repeat revascularization. Multivariable Cox regression models were used for risk-adjustment and propensity matching was also performed. RESULTS: A total of 1853 patients were included in the study (1269 CABG, 584 PCI). CABG was associated with greater 5-year freedom from MACCE (70.1% vs 47.3%, P < 0.0001), a finding that persisted after risk-adjustment. The rates of early and late mortality and readmission were also lower with CABG as were individual rates of myocardial infarction and repeat revascularization. A propensity-matched analysis generated 704 well-matched patients (352 in each arm) with similar results, including greater 5-year freedom from MACCE (72.8% vs 45.8%, P < 0.0001), improved 5-year survival (73.9% vs 52.3%, P < 0.0001), lower readmission (cause-specific hazard ratio 0.68, 95% confidence interval 0.58-0.80; P < 0.0001), lower individual rates of myocardial infarction (2.6% vs 9.7%, P < 0.0001) and repeat revascularization (1.1% vs 7.4%, P < 0.0001). CONCLUSIONS: CABG is associated with a lower MACCE rate than that of PCI in patients with MVCAD and chronic kidney disease. Multidisciplinary discussions regarding the optimal revascularization strategy are important in MVCAD, particularly in more complex scenarios such as chronic kidney disease.
引用
- Kilic A, Sultan I, Gleason TG, et al. Surgical versus percutaneous multivessel coronary revascularization in patients with chronic kidney disease. Eur J Cardiothorac Surg. 2020. PMID: 31808505. doi:10.1093/ejcts/ezz336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。